Multiple system atrophy (MSA) is an orphan, fatal, adult-onset neurodegenerative disorder of
uncertain etiology that is clinically characterized by various combinations of parkinsonism …

The α-synucleinopathies are a group of neurodegenerative diseases characterized by
abnormal accumulation of insoluble α-synuclein in neurons and glial cells, comprising …

Multiple system atrophy (MSA) may be difficult to distinguish clinically from other disorders,
particularly in the early stages of the disease. An autonomic-only presentation can be …

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a
combination of autonomic failure, cerebellar ataxia, and parkinsonism. Laryngeal stridor is …

Background The risk of COVID‐19 and related death in people with Parkinson's disease or
parkinsonism is uncertain. The aim of the study was to assess the risk of hospitalization for …

Objectives To identify the clinical characteristics of the subgroup of benign progressive
supranuclear palsy with particularly long disease duration; to define neuropathological …

Background The genetic basis of variation in the progression of primary tauopathies has not
been determined. We aimed to identify genetic determinants of survival in progressive …

As synucleinopathies, Parkinson's disease (PD) and multiple system atrophy (MSA) are
neurodegenerative diseases that involve the spread of pathogenic alpha-synuclein (αSyn) …

The advent of clinical trials of disease-modifying agents for neurodegenerative disease
highlights the need for evidence-based end point selection. Here we report the longitudinal …

Background Progressive supranuclear palsy (PSP) is a clinically heterogenous atypical
parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is …